Clinical data | |
---|---|
Trade names | Velcade, others |
Other names | PS-341 |
AHFS/Drugs.com | Monograph |
MedlinePlus | a607007 |
License data |
|
Pregnancy category |
|
Routes of administration | Subcutaneous, intravenous |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Protein binding | 83% |
Metabolism | Liver, CYP extensively involved |
Elimination half-life | 9 to 15 hours |
Identifiers | |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
PDB ligand | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.125.601 |
Chemical and physical data | |
Formula | C19H25BN4O4 |
Molar mass | 384.24 g·mol−1 |
3D model (JSmol) | |
| |
| |
(verify) |
Bortezomib, sold under the brand name Velcade among others, is an anti-cancer medication used to treat multiple myeloma and mantle cell lymphoma.[3] This includes multiple myeloma in those who have and have not previously received treatment.[2] It is generally used together with other medications.[2] It is given by injection.[3]
Common side effects include nausea, diarrhea, tiredness, low platelets, fever, numbness, low white blood cells, shortness of breath, rash and abdominal pain.[3] Other severe side effects include low blood pressure, tumour lysis syndrome, heart failure, and reversible posterior leukoencephalopathy syndrome.[3][2] It is in the class of medications known as proteasome inhibitor.[3] It works by inhibiting proteasomes, cellular complexes that break down proteins.[2]
Bortezomib was approved for medical use in the United States in 2003 and in the European Union in 2004.[3][2] It is on the World Health Organization's List of Essential Medicines.[4] It is available as a generic medication.[5]